CbdMD Launches Max Chill Dragon Fruit D9 Gummies: Your Go-To Relaxation Blend for the Summer
CbdMD Launches Max Chill Dragon Fruit D9 Gummies: Your Go-To Relaxation Blend for the Summer
Charlotte, North Carolina--(Newsfile Corp. - May 16, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA) a leading name in premium CBD offerings, is excited to introduce its newest relaxation innovation: "Max Chill" Dragon Fruit D9 Gummies. Crafted to elevate your summer unwind sessions, these gummies boast a distinctive 1:1 CBD to THC ratio, marking a milestone in the brand's selection of high-mg THC products.
北卡羅來納州夏洛特--（Newsfile Corp.，2024年5月16日）——高端CBD產品的領先公司cbdMD, Inc.（紐約證券交易所美國股票代碼：YcbdPA）很高興推出其最新的放鬆創新：“Max Chill” 火龍果D9軟糖。這些軟糖專爲提升您的夏日放鬆體驗而設計，具有獨特的 1:1 CBD 與 THC 的比例，標誌着該品牌精選高毫克四氫大麻酚產品的一個里程碑。
Each gummy contains 10mg of Delta 9 THC and 10mg of CBD, ensuring a balanced experience. This equal ratio harnesses the synergy between THC and CBD to maximize relaxation benefits. CBD's ability to promote relaxation and counteract potential negative sensations associated with THC makes the combination ideal for unwinding and relieving daily stress.
每粒軟糖含有 10 毫克的 Delta 9 四氫大麻酚和 10 毫克的 CBD，確保均衡的體驗。這種相等的比例利用四氫大麻酚和CBD之間的協同作用，最大限度地提高放鬆功效。CBD能夠促進放鬆並抵消與四氫大麻酚相關的潛在負面感覺，因此該組合非常適合放鬆和緩解日常壓力。
"At cbdMD, we're committed to continually enhancing our customers' journeys, and this new product epitomizes that commitment," expressed Ronan Kennedy, CEO at cbdMD. "We formulated this product with a specific goal in mind: to offer a Farm Bill compliant high mg THC product designed to help reduce daily stress and promote relaxation."
cbdMD首席執行官羅南·肯尼迪表示：“在cbdMD，我們致力於不斷改善客戶的旅程，而這款新產品體現了這一承諾。”“我們在配製該產品時考慮了一個具體目標：提供符合農業法案的高毫克四氫大麻酚產品，旨在幫助減輕日常壓力和促進放鬆。”
Key Highlights of Max Chill Dragon Fruit D9 Gummies:
Max Chill 火龍果 D9 軟糖的主要亮點：
- Balanced Formulation: Each gummy contains a precise 1:1 ratio of 10mg Delta 9 THC and 10mg CBD, offering a harmonious blend for relaxation.
- Tropical Flavor: Indulge in the tropical taste of dragon fruit, adding a delightful twist to your experience.
- Vegan and Gluten-Free: Made with vegan-friendly and gluten-free ingredients, catering to diverse dietary preferences.
- High Potency: Formulated as a new feature in our high mg THC product lineup, providing potent relief.
- Quality Assurance: Rigorously tested for purity, potency, and safety, ensuring premium quality backed by third-party lab testing.
- 平衡配方： 每顆軟糖含有 10mg Delta 9 四氫大麻酚和 10mg CBD 的精確 1:1 比例，爲放鬆提供了和諧的混合物。
- 熱帶風味： 盡情享受火龍果的熱帶風味，爲您的體驗增添令人愉悅的味道。
- 純素食和無麩質： 採用素食友好型和無麩質食材製成，可滿足不同的飲食偏好。
- 高效力： 作爲我們高毫克四氫大麻酚產品系列中的一項新功能配方，可有效緩解疼痛。
- 質量保證： 經過嚴格的純度、效力和安全性測試，確保以第三方實驗室測試爲後盾的優質品質。
"We recognize that we have a diverse customer base and some individuals may experience negative side effects with high THC consumption. We were driven to create a product designed to mitigate these effects, targeting a more mellow and tranquil state of mind," continued Kennedy. "Our dedication to providing a premium experience extends to prioritizing our customers' well-being, and we're proud to offer a product that not only delivers on potency but also promotes a positive and enjoyable experience just in time for Summer."
“我們認識到我們擁有多元化的客戶群，有些人可能會因四氫大麻酚攝入量過高而出現負面副作用。我們被迫開發一款旨在減輕這些影響的產品，目標是營造更加柔和、寧靜的心態，” 肯尼迪繼續說道。“我們致力於提供優質體驗延伸到優先考慮客戶的福祉，我們很自豪能夠提供一款不僅能發揮效力，而且能在夏季及時促進積極愉快體驗的產品。”
cbdMD's Max Chill Dragon Fruit D9 Gummies retail for $39.99 and are available for purchase at . Must be 21 years or older to purchase. For more information about cbdMD, please visit cbdmd.com or engage with us on social at @cbdmd.usa.
cbdMD 的 Max Chill 火龍果 D9 軟糖的零售價爲 39.99 美元，可在以下網址購買。必須年滿 21 歲才能購買。有關 cbdMD 的更多信息，請訪問 cbdmd.com 或通過社交賬號 @cbdmd .usa 與我們互動。
About cbdMD, Inc.:
關於 cbdMD, Inc.：
cbdMD, Inc. is one of the leading and most highly trusted and most recognized Cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products, including NSF Certified for Sport products, as well as a wide array of Full Spectrum products. Our cbdMD brand currently includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids, and a growing collection of Farm Act compliant Delta 9 products. Our Paw CBD brand of pet products includes veterinarian-formulated products including tinctures and chews in varying strengths, and our ATRx Labs brand of natural functional mushroom support. To learn more about cbdMD and our comprehensive line of U.S. grown, THC-free1 CBD oil and Full Spectrum products as well as our other brands, please visit , , or ATRxLabs.com, follow cbdMD on Instagram and Facebook, or visit one of the thousands of retailers nationwide that carry cbdMD's products.
cbdMD, Inc. 是領先的、最值得信賴和最受認可的大麻二酚（CBD）品牌之一，擁有美國生產的全系列不含四氫大麻酚1 CBD 產品，包括經過 NSF 認證的運動產品，以及各種全譜產品。我們的cbdMD品牌目前包括高檔的優質CBD產品，包括CBD酊劑、CBD軟糖、CBD外用藥、CBD膠囊、CBD助眠劑，以及越來越多的符合農場法案的Delta 9產品。我們的 Paw CBD 品牌寵物產品包括獸醫配方的產品，包括不同強度的酊劑和咀嚼劑，以及我們的 ATrX Labs 品牌的天然功能性蘑菇支持劑。要詳細了解 cbdMD 和我們在美國種植、不含四氫大麻酚的全系列產品1 CBD石油和全譜產品以及我們的其他品牌，請訪問或atrxLabs.com，在Instagram和Facebook上關注cbdMD，或訪問全國數千家銷售cbdMD產品的零售商中的一家。
Forward-Looking Statements:
前瞻性陳述：
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified using words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict. You are urged to carefully review and consider any cautionary statements, including but not limited to federal and state CBD regulation, and other disclosures, including the statements made under the heading "Risk Factors" in cbdMD, Inc.'s Annual Report on Form 10-K for the fiscal year ended September 30, 2023 as filed with the Securities and Exchange Commission (the "SEC") and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release.
本新聞稿包含某些前瞻性陳述，這些陳述基於當前預期，涉及1995年《美國私人證券訴訟改革法》所指的某些風險和不確定性。此類前瞻性陳述可以使用 “應該”、“可能”、“打算”、“預期”、“相信”、“估計”、“項目”、“預測”、“期望”、“計劃” 和 “提議” 等詞語來識別。這些前瞻性陳述不能保證未來的表現，並且受風險、不確定性和其他因素的影響，其中一些因素是我們無法控制的，難以預測。我們敦促您仔細審查和考慮任何警示性聲明，包括但不限於聯邦和州CBD法規，以及其他披露，包括cbdMD, Inc.在 “風險因素” 標題下發表的聲明。”向美國證券交易委員會（“SEC”）提交的截至2023年9月30日財年的10-K表年度報告以及我們向美國證券交易委員會提交的其他文件。所有前瞻性陳述都涉及重大風險和不確定性，可能導致實際結果與前瞻性陳述存在重大差異，其中許多前瞻性陳述通常不在cbdMD, Inc.的控制範圍之內，難以預測。除非法律要求，否則cbdMD, Inc.不承擔任何更新任何前瞻性陳述的責任。出現在我們的網站和社交媒體平台（包括但不限於Instagram和Facebook）上的信息不在本新聞稿中。
Contact Information:
cbdMD, Inc.
Ronan Kennedy, CEO
+1 (704) 445-3064
IR@cbdmd.com
聯繫信息：
cbdMD, Inc.
首席執行官羅南·肯尼迪
+1 (704) 445-3064
IR@cbdmd.com
譯文內容由第三人軟體翻譯。